Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
. 2016 Aug;22(5):241-7.
doi: 10.1097/RHU.0000000000000364.

Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis

Affiliations
Free PMC article

Rates of Cancers and Opportunistic Infections in Patients With Psoriatic Arthritis Compared With Patients Without Psoriatic Arthritis

Katrina Wilcox Hagberg et al. J Clin Rheumatol. .
Free PMC article

Abstract

Objectives: This study aimed to estimate rates of cancer or opportunistic infection in patients with psoriatic arthritis (PsA) compared with patients without PsA.

Methods: Using the Clinical Practice Research Datalink, we conducted a cohort study of patients with a PsA diagnosis and patients without such diagnosis, matched on age, sex, general practice, and calendar time, to assess the incidence of cancers (solid, hematologic, and nonmelanoma skin cancer) and opportunistic infections. We estimated incidence rates (IRs) and IR ratios (IRRs) with 95% confidence intervals (CIs) for each outcome and stratified results in the PsA cohort by receipt of systemic PsA drugs.

Results: The rate of hematologic cancer was slightly higher in the PsA cohort compared with the non-PsA cohort (IRR, 1.52; 95% CI, 1.10-2.10), whereas the rates of solid cancer and of nonmelanoma skin cancer were similar between the PsA and non-PsA cohorts (IRR, 1.01; 95% CI, 0.90-1.13; and IRR, 0.97; 95% CI, 0.82-1.14, respectively). Incidence rates were higher for PsA patients who received prescriptions for PsA drugs compared with those who did not. The IRs for infection were higher in the PsA compared with the non-PsA cohort (IRR, 1.39; 95% CI, 1.31-1.47) and were significantly higher in patients who received prescriptions (IRR, 1.71; 95% CI, 1.52-1.91).

Conclusions: The rates of solid and nonmelanoma skin cancers were similar in patients with PsA compared with patients without PsA, but the rates of hematologic cancer and opportunistic infections were higher in patients with PsA. In patients with PsA, rates of all outcomes were higher among those who received prescriptions for systemic PsA therapy.

Figures

FIGURE 1
FIGURE 1
Cumulative incidence of solid cancer in the PsA and comparison cohorts.
FIGURE 2
FIGURE 2
Cumulative incidence of hematologic cancer in the PsA and comparison cohorts.
FIGURE 3
FIGURE 3
Cumulative incidence of nonmelanoma skin cancer in the PsA and comparison cohorts.
FIGURE 4
FIGURE 4
Cumulative incidence of opportunistic infections in the PsA and comparison cohorts.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Rohekar S, Tom BD, Hassa A, et al. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum. 2008;58:82–87. - PubMed
    1. Hellgren K, Smedby KE, Backlin C, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol. 2014;66:1282–1290. - PubMed
    1. Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66:1472–1481. - PMC - PubMed
    1. Kimball AB, Schenfeld J, Accortt NA, et al. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09. Br J Dermatol. 2014;170:366–373. - PubMed
    1. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70:616–623. - PubMed

Substances

Feedback